Examination of prolidase and IL -37 level in patients with fibromyalgia syndrome

Fibromyalgia is characterized by chronic, widespread musculoskeletal pain and associated fatigue, sleep disturbances, and other cognitive symptoms. For many patients, these symptoms persist for years and often result in seeking health care. Current biomedical and psychosocial treatments are insufficient for many patients and treatment has not progressed due to the lack of a clear understanding of the pathogenesis of fibromyalgia. Fibromyalgia is diagnosed more frequently in women than in men, and its etiology is unknown. For clinicians, they can diagnose and treat FM more effectively if its underlying mechanisms are better understood. In our study, prolidase and IL-37 levels, which we think may have a role in the diagnosis and treatment of fibromyalgia, were examined. Blood samples were taken from 43 female patients with fibromyalgia diagnosis and 40 healthy control group who applied to Harran University Faculty of Medicine Physical Medicine and Rehabilitation clinic. Prolidase and IL-37 levels in serum samples obtained from blood samples were analyzed by ELISA method. As a result of the statistical analysis, the mean prolidase and IL-37 levels in patients diagnosed with FMS were found to be significantly higher (p<0.001) compared to the control group. No significant correlation (P>0.05) was observed in prolidase and IL-37 levels in the patient and control groups. As a result of the study, it was concluded that this study should be investigated in more patient groups, as it was seen that prolidase and IL-37 have a role in order to elucidate the pathophysiology of FMS and to develop new strategies for the treatment of the disease